AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02701205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: etanercept (half dose)
Description: Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
Study NCT02701205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: two vials of placebo twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
Study NCT02340884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Resilience In Stress Management (PRISM)
Description: The brief format of the PRISM intervention involves 4, 50-minute, one-on-one sessions approximately 2 weeks apart, plus a 5th parent-inclusive session 2-4 weeks following session #4. These are complimented with age-specific handouts describing the skills and opportunities to practice them, as well as weekly (text- or email based) check-ins from study staff and in-person booster sessions once monthly. Specifically, the intervention incorporates four primary skills: 1) stress management/mindfulness; 2) goal-setting; 3) cognitive restructuring; and, 4) meaning-making/benefit finding.
Study NCT02710188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0009936 modified release
Description: HTL0009936 modified release
Study NCT02710188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTL0009936 immediate release
Description: HTL0009936 immediate release
Study NCT04298619 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standard cohort: Clinical lab follow-up
Study NCT04298619 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging cohort: integrated imaging follow-up
Study NCT05812326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells
Description: AJMUC1 is a genetically modified T cell therapeutic product targeting the aberrantly glycosylated MUC1 protein. CAR targeting MUC1 is introduced into autologous T cells by lentiviral vector, so that T cells expressing the receptor can recognize and kill MUC1 positive tumor cells. Preclinical studies have shown that binding of scFv targeting MUC1 to the MUC1 epitope on the surface of the target cell can induce the costimulatory CD28 and CD3ζ costimulatory domains to activate downstream signaling pathways and promote T cell activation and expansion. Activated CAR-T cells secrete a series of inflammatory cytokines and chemokines, leading to apoptosis and necrosis of target tumor cells. Following introduction of a CAR structure, the PD-1 gene of CAR-T cells is knocked out using CRISPR/Cas9, so that the CAR-T cell does not express PD-1, resulting in improved tumor killing efficiency of AJMUC due to the release of inhibition in the signaling pathway PD-1/PD-L1 in the tumor microenvironment.
Study NCT01011114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet
Description: cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
Study NCT01011114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
Study NCT03942224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC
Study NCT03942224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study NCT03942224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV and PO
Study NCT03942224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given PO
Study NCT02544854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:~1. First 15 minutes: 15 mg/kg/min~2. 16 to 30 minutes: 13 mg/kg/min~3. 31 to 60 minutes: 11 mg/kg/min~4. 61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.~Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:~1. 5, 15 and 25 minutes of starting infusion,~2. 1, 3, 5, 7, 9 and 12 minutes of bolus and,~3. 5, 25, 60 and 120 minutes of infusion ended.
Study NCT01357343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chiropractic
Description: Spinal manipulation and active and passive therapy.
Study NCT01357343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture needling, moxa, Tui Na and cupping.
Study NCT00335166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pardaprunox
Description: 12-42 mg
Study NCT00335166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole
Description: 1.5-4.5 mg
Study NCT00335166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo
Study NCT00744016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulated mesalamine
Description: 0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning
Study NCT00744016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules (4 capsules) were administered orally QD, in the morning
Study NCT02726113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: softgels 4000 IU daily for approximately two months prior to surgery (prostatectomy).
Study NCT02726113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: softgel containing no active ingredient daily for approximately two months prior to surgery (prostatectomy).
Study NCT03866148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reveal LINQ
Description: Insertion of monitoring device called Reveal-LINQ (an implantable loop recorder)
Study NCT00030615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT00030615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00030615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00790179 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA
Description: 0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.~Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA.
Study NCT00593658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline
Description: pentoxifylline extended release 800mg PO TID for 8 weeks
Study NCT01641991 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax®
Description: BioThrax® is a sterile, milky white suspension made from cell free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis, will be administered as a 0.50mL IM injection 6 month boost for all groups
Study NCT01641991 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax®
Description: BioThrax® will be administered as: Arm A: 0.50mL SC injection on Days 0 and 14; Arm B: 0.50mL SC injection on Days 0 and 28; Arm C: 0.50mL SC injection on Days 0, 14 and 28; Arm D: 0.25 mL SC injection on Days 0, 14 and 28.
Study NCT05256082 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: six-minutes-walking test
Description: Patients conducting a six-minutes-walking test
Study NCT05256082 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: six-minutes-walking test
Description: Patients conducting a six-minutes-walking test
Study NCT03685552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prog: Purify-2
Description: Nutritional Supplements to be administered:~* Protein Shakes: one protein shake twice a day~* Probiotics (Bacillus Coagulans) once a day~* Biome NO+ ( blend of amino acids, specifically l-arginine and l-citrulline, combined with red beet root, grape polyphenol extract, vitamins and minerals) twice a day~* In.Form Purify ( blend of psyllium hull, inulin, L-glutamine, fruit, fruit extracts and zinc) twice a day
Study NCT00765219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: 10-12 weekly sessions of CBT in person or over the telephone.
Study NCT00765219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Treatment as usual provided by participants' physician(s)
Study NCT01585402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etidronate
Description: Didronel (etidronate disodium)- Didronel tablets contain either 200 mg or 400 mg of etidronate disodium, the disodium salt of (1-hydroxyethylidene) diphosphonic acid, for oral administration. This compound, also known as EHDP. regulates bone metabolism. It is a white powder, highly soluble in water. The 400 mg tablets are white capsule-shaped tablets with ED 400 on one side and G on the other side.
Study NCT01585402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: Visit on day 0 and visit at 36 month - Exploratory MRI studies may be employed to evaluate the lumen of the artery and degree of collateral vessels, given that the high degree of calcification is precluding that evaluation by CT.
Study NCT03941847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: listening music
Study NCT00434499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGCG
Description: EGCG 400 mg by mouth twice/daily for 4 weeks duration.
Study NCT03803592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic MCS program
Description: In the first 4 weeks, the dyads will attend the center-based FTF sessions. Each session will last for 1.5 hours. In the first 60 minutes, MCS activities (e.g. reality orientation, calculation and drawing) will be led by an occupational therapist. Skills in delivering the MCS activities will also be taught to equip CG with skills in leading the home-based sessions later. CG will leave in the last 30 minutes to attend a psychoeducation group on caregiving (led by social workers) and the PWD will continue the session.~From week 5 onwards, The home based session (Week 5-15) will be delivered by the CG 3 times weekly at home (30 - 45min/ session).The sessions will be supplemented with weekly telephone follow-up and two FTF sharing sessions held on the 8th and 12th week over the period.
Study NCT02590289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-5000
Description: BBI-5000 low dose, middle dose, or high doses
Study NCT02588469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventional group
Description: Venous compression leads to beneficial fluid regulation in OSA participants and appears as an efficient tool in OSA management.~To the investigators knowledge no study assess the impact of the cumulative effect of physical and venous compression program on upper airway resistances in obese teenager with OSA.
Study NCT02588469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Standard obesity care with physical activity program
Study NCT02184676 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Analysis of early immune modifications
Description: * blood and stool sampling in parents during pregnancy (at enrollment, i.e. 7th-8th month of pregnancy)~* cord blood sampling~* stool sampling in mothers and newborns at birth (day 7)~* blood and stool sampling in children at the age of 8, 18, 30 and 42 months
Study NCT02184676 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of clinical and socio-demographic data
Description: 1. Questionnaire filled in by clinicians at enrollment and at birth~2. Self-administered questionnaire filled by parents at enrollment, at birth, and then at month 8, 18, 30 and 42
Study NCT00544856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: complex cognitive training
Study NCT00544856 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: complex cognitive training
Study NCT05407103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Acupressure
Description: For the cold acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the cold acupressure pouches were kept in a freezer for 40 minutes.
Study NCT05407103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm Acupressure
Description: For the warm acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the warm acupressure pouches were heated in a microwave at 600 W for one minute.
Study NCT03168802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRgFUS ablation
Description: Focus ultrasound ablation therapy under MRI navigation for facet joint syndrome.
Study NCT03168802 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation therapy under C-arm navigation for facet joint syndrome.
Study NCT02007954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEBDOX
Description: DEBDOX, loaded with doxorubicin, is a device that utilizes beads in place of lipiodol to deliver the chemotherapy into the liver tumor. The device allows for continuous elution of doxorubicin into the liver tumor tissue. The advantages of this method of delivery in comparison to conventional TACE are that the beads are able to deliver a greater volume and concentration of the drugs to the tumor because of their unique ability to elute the drug over a period of several days. As a result of this unique delivery, systemic toxicity is significantly reduced. The potential advantages of the smaller beads are deeper penetration into the tumor bed, while avoiding premature proximal occlusion of vessels feeding the tumor, and more consistent dosing. These properties translate into greater potency of therapy and potentially improved patient survival.
Study NCT03668535 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Filling
Description: Group A have a triple-way urethral catheter insertion before establishment of anaesthesia. Evaluation of the drained urine is done (including: amount, character, and simple for culture and sensitivity). Instillation of 200 ml sterile saline is done by 50 ml syringe through the irrigation way. The irrigation way is closed temporarily by artery forceps. After laparotomy the bladder may be deflated by 50 ml or further inflated by 50 ml if needed to allow comfortable dissection.
Study NCT03710889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Description: Abaloparatide is a novel, synthetic, 34 amino acid peptide designed to be a potent and selective activator of the PTH/PTH-related protein (PTHrP) type 1 receptor (PTHR1) signaling pathway with 41% homology to PTH\[1-34\] and 76% homology to human PTHrP\[1-34\].
Study NCT01597726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol 400 mcg administered buccally approximately 3-6 hours prior to D\&E, repeated once 3 hours after the first dose if needed
Study NCT01597726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laminaria
Description: Laminaria tents inserted into the cervix 18 to 24 hours prior to D\&E
Study NCT00578032 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment
Description: All patients will complete the predefined questionnaires at the following four time points along the course of their care: preoperative clinic visit, and 3 months (±1 month), 6 months (±1), and 9 months (1 and +3) post-operatively. Completion of the questionnaires should take approximately 30 minutes
Study NCT03668535 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bladder deflation
Description: Group B have Foley's catheter is inserted as usual. The catheter is connected freely to urinary bag.
Study NCT04511221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animals subsp. lactis BL04
Description: One 15mg capsule taken orally each day
Study NCT04511221 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One 15mg capsule taken orally each day
Study NCT02527499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ride-On Cars with Bimanual Training Program (ROCBT)
Description: The car driving training includes 2 phases: I-car exploration and II-prompted driving. Participants can learn how to move and stop the car in the car exploration phase. Through prompted driving in phase II, they can use the car as a mean to explore environments (e.g., to the elevator, to different stores) and contact with people (e.g., drive to the caregiver and get the toy). Bimanual training involves activities which include perceptual motor tasks (e.g., smear both hands with color), holding and manipulative tasks (e.g., cutting toy vegetables or fruits), posture and balance (e.g., pull a cart), and self-care and activities of daily living (e.g., drinking water from a cup with two handles).
Study NCT02527499 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Mobility Training Program
Description: Most of the guidelines are similar with ROCBT, except for the bimanual training. The therapist and family will merely focus on independent mobility training and improving socialization. The training time and period is the same as ROCBT.
Study NCT02527499 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular Therapy Program
Description: The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance at the hospital for 1 hour/per session, 1 session/per week during the 9-week intervention phase.
Study NCT01576874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IUs of oxytocin administered intranasally one time
Study NCT01576874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered intranasally one time
Study NCT01610739 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Indigocyanine green dye
Description: Each patient will receive 1 injection of indigocyanine green dye using 2.5 mg/mL concentration of the imaging agent. 3mL of this mixture will be injected intravenously, followed by 10mL NS bolus, just prior to imaging with the SPY scope
Study NCT01081158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)
Description: Drug: SCH 900518~Biologic: Peginterferon alfa-2b(PegIntron)~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days .~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly.
Study NCT02726893 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT04056871 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty Screening Tools
Description: This is an observational and prospective study of patients who are going for elective surgery, thus no intervention will be given.
Study NCT04490317 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: 1. Cardiac MRI be taken to CO poisoned patients~2. Cardiac CT be taken to CO poisoned patients~3. TTE be taken to CO poisoned patients~4. Brain MRI be taken to CO poisoned patients~5. Neurocognitive function tests be taken to CO poisoned patients~6. Laboratory tests be taken to CO poisoned patients
Study NCT04490317 — intervention group
Intervention type: PROCEDURE
Intervention: Hyperbaric oxygen therapy
Description: 1. Hyperbaric oxygen therapy be used for CO poisoned patients~2. Therapeutic hypothermia be used for CO poisoned patients
Study NCT02220946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Electrical Stimulation
Description: A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off. the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. each patient received a 20 minute session once a week for total 8 session
Study NCT02039466 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: volume controlled ventilation
Study NCT02039466 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pressure controlled ventilation